# A Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine/Cervarix TM Vaccine in Healthy Females Aged 15-25 Years

> **NCT00485732** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 225 (actual)

## Conditions studied

- Infections, Papillomavirus

## Interventions

- **BIOLOGICAL:** HPV-16/18 VLP/AS04 vaccine (Cervarix TM)
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT00485732
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-06-11
- **Primary completion:** 2008-03-30
- **Final completion:** 2008-03-30
- **Target enrollment:** 225 (ACTUAL)
- **Last updated:** 2018-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00485732

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00485732, "A Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine/Cervarix TM Vaccine in Healthy Females Aged 15-25 Years". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00485732. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*